Metformin ER / working resource
Observation and follow-up journal
Record what changed, when it changed and what else could explain it.
Start with the product-specific question
The boxed warning
Metformin ER, approved for type 2 diabetes, with the evidence and its limits for other uses in plain view. What should I know about the lactic acidosis warning?
Open the Metformin ER library ↗In the 15-year follow-up of the Diabetes Prevention Program Outcomes Study, the cumulative incidences of diabetes at year 15 were 55% in the lifestyle group, 56% in the metformin group, and 62% in the placebo group.
Read the original record ↗
Describe an observation without assuming a cause.
When researching Metformin ER, stories about improvement can leave out other changes, time trends and ordinary variation. A clear record preserves those details. Use any monitoring plan agreed with your clinician; this blank journal does not supply one.
Entry 1
Entry 2
Entry 3
Entry 4
Review the record with context.
A personal timeline cannot establish that a product caused a benefit or harm. Seek appropriate care for concerning symptoms rather than waiting to complete a journal.
These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.